177 is the total number of securities Stonepine Capital Management, LLC has owned. The longest Stonepine Capital Management, LLC has owned a single stock is 24 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| CTIC | CTI Biopharmap Corp. | 24 | 24 | 1.87% | 7.27% | 14.83% | Q2 2017 | Q1 2023 | 24 |
| APEN | APOLLO ENDOSURGERY INC | 23 | 23 | 1.23% | 5.89% | 15.63% | Q3 2017 | Q1 2023 | 23 |
| XOMA | XOMA CORP | 19 | 1 | 0.35% | 2.33% | 5.75% | Q1 2017 | Q3 2023 | 20 |
| CPIX | Cumberland Pharmaceuti... | 19 | 19 | 0.43% | 3.61% | 6.96% | Q2 2016 | Q4 2020 | 19 |
| AMRN | Amarin Corp PLC - SPON... | 10 | 1 | 0.04% | 9.66% | 23.18% | Q2 2017 | Q3 2022 | 14 |
| VNDA | VANDA PHARMACEUTICALS INC | 10 | 1 | 0.34% | 8.61% | 20.93% | Q4 2015 | Q3 2023 | 14 |
| BDSI | BIODELIVERY SCIENCES INTL | 12 | 1 | 0.03% | 5.61% | 12.94% | Q1 2016 | Q1 2020 | 14 |
| AFMD | AFFIMED NV | 6 | 2 | 0.22% | 2.85% | 7.66% | Q4 2018 | Q3 2022 | 13 |
| ALIM | ALIMERA SCIENCES INC | 13 | 13 | 0.14% | 2.75% | 4.15% | Q3 2016 | Q3 2019 | 13 |
| VIVE | VIVEVE MEDICAL INC | 12 | 12 | 0.89% | 8.41% | 15.31% | Q3 2016 | Q2 2019 | 12 |
| NVLNF | NOVELION THERAPEUTICS INC | 9 | 3 | 0.26% | 4.39% | 9.44% | Q4 2016 | Q4 2019 | 12 |
| NEOS | NEOS THERAPEUTICS INC | 10 | 1 | 0.65% | 3.92% | 6.77% | Q2 2017 | Q4 2020 | 12 |
| DMAC | DIAMEDICA THERAPEUTICS... | 10 | 1 | 0.03% | 2.94% | 8.97% | Q1 2019 | Q2 2022 | 12 |
| AMYT | AMRYT PHARMA PLC - SPN... | 11 | 11 | 9.84% | 21.41% | 31.80% | Q3 2020 | Q1 2023 | 11 |
| ADMS | ADAMAS PHARMACEUTICALS... | 11 | 11 | 2.68% | 5.24% | 8.86% | Q1 2019 | Q3 2021 | 11 |
| EOLS | EVOLUS INC | 5 | 1 | 0.29% | 4.47% | 15.72% | Q1 2018 | Q3 2023 | 11 |
| XGN | EXAGEN INC | 11 | 11 | 0.84% | 2.05% | 4.58% | Q1 2021 | Q3 2023 | 11 |
| LGND | LIGAND PHARMACEUTICALS | 4 | 3 | 2.90% | 12.75% | 31.88% | Q1 2019 | Q3 2022 | 10 |
| ADMA | ADMA BIOLOGICS INC | 8 | 1 | 0.13% | 6.85% | 11.70% | Q4 2017 | Q3 2023 | 10 |
| ENTA | ENANTA PHARMACEUTICALS... | 5 | 1 | 2.75% | 5.69% | 10.76% | Q4 2015 | Q1 2022 | 10 |
| OPHT | OPHTHOTECH CORP | 10 | 10 | 2.34% | 4.53% | 7.25% | Q4 2016 | Q1 2019 | 10 |
| CFMS | CONFORMIS INC | 8 | 2 | 0.30% | 2.43% | 5.16% | Q1 2018 | Q4 2022 | 10 |
| ISEE | IVERIC BIO INC | 9 | 9 | 1.71% | 9.44% | 27.06% | Q2 2019 | Q2 2021 | 9 |
| BSTC | BioSpecifics Technolog... | 7 | 2 | 1.05% | 7.51% | 14.02% | Q1 2016 | Q4 2018 | 9 |
| REPH | RECRO PHARMA INC | 9 | 9 | 1.23% | 7.03% | 14.16% | Q4 2015 | Q4 2017 | 9 |
| OXFD | OXFORD IMMUNOTEC GLOBA... | 7 | 1 | 1.26% | 3.71% | 11.00% | Q3 2017 | Q1 2020 | 9 |
| OPNT | OPIANT PHARMACEUTICALS... | 7 | 2 | 0.74% | 2.78% | 4.59% | Q3 2018 | Q3 2022 | 9 |
| SBBP | STRONGBRIDGE BIOPHARMA... | 5 | 1 | 0.35% | 2.19% | 5.13% | Q4 2017 | Q3 2021 | 9 |
| CDTX | CIDARA THERAPEUTICS INC | 5 | 1 | 0.00% | 1.20% | 3.42% | Q2 2018 | Q1 2023 | 9 |
| XERIS BIOPHARMA HOLDIN... | 8 | 8 | 3.66% | 6.66% | 9.07% | Q4 2021 | Q3 2023 | 8 | |
| CBIO | CATALYST BIOSCIENCES INC | 8 | 8 | 1.46% | 5.16% | 6.97% | Q4 2019 | Q3 2021 | 8 |
| VCEL | VERICEL CORP | 8 | 8 | 2.34% | 4.85% | 9.80% | Q4 2015 | Q3 2017 | 8 |
| CHMA | CHIASMA INC | 4 | 1 | 0.53% | 4.25% | 16.75% | Q1 2019 | Q2 2021 | 8 |
| HTGM | HTG MOLECULAR DIAGNOSTICS | 8 | 8 | 0.34% | 3.07% | 5.97% | Q2 2018 | Q1 2020 | 8 |
| RZLT | REZOLUTE INC | 8 | 8 | 1.05% | 2.39% | 4.51% | Q4 2021 | Q3 2023 | 8 |
| LIFE | ATYR PHARMA INC | 5 | 3 | 0.79% | 1.98% | 3.60% | Q3 2021 | Q3 2023 | 8 |
| OVID | OVID THERAPEUTICS INC | 7 | 7 | 1.27% | 4.37% | 5.90% | Q1 2021 | Q3 2022 | 7 |
| CRME | CARDIOME PHARMA CORP | 7 | 7 | 2.97% | 4.18% | 5.19% | Q3 2016 | Q1 2018 | 7 |
| VCYT | VERACYTE INC | 6 | 1 | 0.96% | 3.02% | 4.83% | Q2 2016 | Q1 2018 | 7 |
| QUIDELORTHO CORP | 6 | 6 | 5.42% | 12.53% | 18.51% | Q2 2022 | Q3 2023 | 6 | |
| SCLN | SCICLONE PHARMACEUTICA... | 3 | 3 | 1.28% | 12.04% | 26.58% | Q4 2015 | Q2 2017 | 6 |
| GLPG | GALAPAGOS NV-SPON ADR | 4 | 1 | 0.42% | 6.54% | 10.14% | Q1 2021 | Q3 2023 | 6 |
| CUTR | CUTERA INC | 5 | 1 | 1.24% | 3.18% | 5.03% | Q4 2015 | Q2 2017 | 6 |
| URGN | UROGEN PHARMA LTD | 6 | 6 | 0.97% | 3.02% | 4.87% | Q1 2022 | Q2 2023 | 6 |
| GMDA | GAMIDA CELL LTD | 4 | 2 | 1.04% | 1.97% | 3.08% | Q4 2020 | Q3 2023 | 6 |
| SCYX | SCYNEXIS INC | 3 | 1 | 0.00% | 1.63% | 4.01% | Q4 2020 | Q3 2023 | 6 |
| FOMX | FOAMIX PHARMACEUTICALS... | 4 | 1 | 0.01% | 1.49% | 4.08% | Q2 2017 | Q2 2019 | 6 |
| DRRX | DURECT CORPORATION | 5 | 1 | 0.10% | 1.37% | 2.68% | Q2 2016 | Q3 2019 | 6 |
| ALR | Alere Inc. | 5 | 5 | 2.71% | 6.11% | 10.11% | Q2 2016 | Q2 2017 | 5 |
| OPTN | OPTINOSE INC | 5 | 5 | 0.40% | 2.80% | 4.46% | Q4 2021 | Q4 2022 | 5 |
| ATRS | ANTARES PHARMA INC | 3 | 1 | 0.38% | 2.66% | 5.32% | Q1 2020 | Q1 2022 | 5 |
| KALV | KALVISTA PHARMACEUTICA... | 3 | 1 | 0.37% | 2.42% | 5.86% | Q3 2018 | Q3 2021 | 5 |
| CELC | CELCUITY INC | 5 | 5 | 0.84% | 1.68% | 2.75% | Q1 2021 | Q1 2022 | 5 |
| TBRA | TOBIRA THERAPEUTICS INC | 4 | 4 | 8.04% | 12.46% | 23.78% | Q4 2015 | Q3 2016 | 4 |
| Aegerion Pharmaceutica... | 4 | 4 | 7.48% | 10.22% | 13.01% | Q2 2016 | Q1 2017 | 4 | |
| MAXCYTE INC | 4 | 4 | 0.63% | 3.90% | 6.57% | Q4 2022 | Q3 2023 | 4 | |
| YMTX | YUMANITY THERAPEUTICS INC | 4 | 4 | 1.42% | 2.41% | 3.28% | Q4 2020 | Q3 2021 | 4 |
| CORV | CORREVIO PHARMA CORP | 3 | 1 | 0.93% | 2.12% | 4.43% | Q2 2018 | Q3 2019 | 4 |
| APVO | APTEVO THERAPEUTICS INC | 4 | 4 | 1.91% | 2.07% | 2.40% | Q1 2019 | Q4 2019 | 4 |
| CSTL | CASTLE BIOSCIENCES INC | 3 | 1 | 0.46% | 1.87% | 3.02% | Q2 2022 | Q2 2023 | 4 |
| DSCI | DERMA SCIENCES INC | 4 | 4 | 0.37% | 1.52% | 2.72% | Q4 2015 | Q3 2016 | 4 |
| CGIX | CANCER GENETICS INC | 4 | 4 | 0.37% | 1.17% | 1.98% | Q4 2017 | Q3 2018 | 4 |
| TRIB | Trinity Biotech PLC - ... | 4 | 4 | 0.41% | 1.10% | 1.80% | Q4 2016 | Q3 2017 | 4 |
| SYBX | SYNLOGIC INC | 4 | 4 | 0.05% | 0.92% | 1.39% | Q3 2021 | Q2 2022 | 4 |
| ANIP | ANI PHARMACEUTICALS INC | 3 | 1 | 0.07% | 0.47% | 1.11% | Q1 2016 | Q2 2022 | 4 |
| AVIR | Aviragen Therapeutics,... | 4 | 4 | 0.12% | 0.33% | 0.54% | Q2 2016 | Q1 2017 | 4 |
| PTIE | PAIN THERAPEUTICS INC | 3 | 3 | 6.37% | 7.66% | 9.28% | Q4 2015 | Q2 2016 | 3 |
| SGNT | SAGENT PHARMACEUTICALS... | 3 | 3 | 4.78% | 6.29% | 8.63% | Q4 2015 | Q2 2016 | 3 |
| CTIC | CTI BIOPHARMA CORP | 2 | 1 | 0.64% | 6.13% | 15.42% | Q4 2015 | Q4 2016 | 3 |
| AVDL | AVADEL PHARMACEUTICALS... | 3 | 3 | 4.10% | 4.89% | 6.10% | Q1 2017 | Q3 2017 | 3 |
| THIRD HARMONIC BIO INC | 3 | 3 | 3.65% | 4.27% | 4.85% | Q4 2022 | Q2 2023 | 3 | |
| PCRX | PACIRA PHARMACEUTICALS... | 2 | 1 | 0.04% | 3.38% | 8.30% | Q2 2016 | Q3 2017 | 3 |
| SCMP | Sucampo Pharmaceutical... | 2 | 1 | 0.07% | 1.59% | 2.40% | Q1 2016 | Q4 2016 | 3 |
| ANGN | ANGION BIOMEDICA CORP | 3 | 3 | 1.24% | 1.36% | 1.52% | Q1 2021 | Q3 2021 | 3 |
| ATEC | ALPHATEC HOLDINGS INC | 3 | 3 | 0.68% | 1.27% | 1.64% | Q2 2018 | Q4 2018 | 3 |
| EYPT | EYEPOINT PHARMACEUTICA... | 3 | 3 | 0.38% | 1.21% | 1.81% | Q1 2021 | Q3 2021 | 3 |
| AVIR | ATEA PHARMACEUTICALS INC | 3 | 3 | 0.77% | 1.17% | 1.71% | Q1 2023 | Q3 2023 | 3 |
| AGTC | APPLIED GENETIC TECHNO... | 2 | 1 | 0.00% | 0.84% | 2.04% | Q1 2020 | Q2 2021 | 3 |
| IDXG | INTERPACE DIAGNOSTICS ... | 3 | 3 | 0.66% | 0.81% | 0.90% | Q1 2019 | Q3 2019 | 3 |
| INTERPACE BIOSCIENCES INC | 2 | 1 | 0.33% | 0.74% | 0.98% | Q4 2019 | Q3 2020 | 3 | |
| ACER | ACER THERAPEUTICS INC | 2 | 1 | 0.06% | 0.41% | 0.83% | Q4 2017 | Q4 2019 | 3 |
| SCYX | SCYNEXIS INC | 1 | 1 | 0.27% | 0.32% | 0.39% | Q1 2018 | Q4 2019 | 3 |
| CFRX | CONTRAFECT CORP | 3 | 3 | 0.06% | 0.31% | 0.70% | Q1 2021 | Q3 2021 | 3 |
| AMYLYX PHARMACEUTICALS... | 2 | 2 | 8.72% | 12.01% | 15.30% | Q2 2023 | Q3 2023 | 2 | |
| QLTI | QLT Inc. | 2 | 2 | 5.50% | 7.60% | 9.71% | Q2 2016 | Q3 2016 | 2 |
| PTX | PERNIX THERAPEUTICS HO... | 2 | 2 | 3.98% | 6.28% | 8.59% | Q4 2015 | Q1 2016 | 2 |
| AYTU | AYTU BIOSCIENCE INC | 2 | 2 | 1.49% | 3.95% | 6.40% | Q4 2020 | Q1 2021 | 2 |
| XFOR | X4 PHARMACEUTICALS, INC. | 2 | 2 | 1.91% | 2.57% | 3.22% | Q2 2023 | Q3 2023 | 2 |
| MLNT | MELINTA THERAPEUTICS INC | 2 | 2 | 0.20% | 2.36% | 4.52% | Q2 2018 | Q3 2018 | 2 |
| CDNA | CAREDX INC | 1 | 1 | 0.11% | 2.08% | 4.05% | Q2 2017 | Q4 2017 | 2 |
| FLML | Flamel Technologies - ... | 1 | 1 | 1.41% | 1.71% | 2.02% | Q2 2016 | Q4 2016 | 2 |
| TELA | TELA BIO INC | 2 | 2 | 1.31% | 1.54% | 1.76% | Q2 2023 | Q3 2023 | 2 |
| MEDICREA INTERNATIONAL | 2 | 2 | 1.49% | 1.51% | 1.54% | Q4 2017 | Q1 2018 | 2 | |
| DOVA | DOVA PHARMACEUTICALS INC | 1 | 1 | 0.08% | 1.38% | 2.67% | Q1 2018 | Q3 2018 | 2 |
| PERNIX THERAPEUTICS HO... | 2 | 2 | 1.28% | 1.34% | 1.42% | Q2 2016 | Q3 2016 | 2 | |
| STDY | STEADYMED LTD | 2 | 2 | 1.26% | 1.31% | 1.37% | Q4 2017 | Q1 2018 | 2 |
| RIGL | RIGEL PHARMACEUTICALS INC | 1 | 1 | 0.02% | 1.30% | 2.57% | Q2 2018 | Q1 2020 | 2 |
| CATB | CATABASIS PHARMACEUTIC... | 2 | 2 | 1.01% | 1.21% | 1.40% | Q2 2018 | Q3 2018 | 2 |
| PROG | PROGENITY INC | 2 | 2 | 0.64% | 1.16% | 1.68% | Q2 2020 | Q3 2020 | 2 |
| EBS | EMERGENT BIOSOLUTIONS INC | 1 | 1 | 0.89% | 1.13% | 1.36% | Q1 2017 | Q1 2019 | 2 |
| SPNE | SEASPINE HOLDINGS CORP | 1 | 1 | 0.06% | 1.12% | 2.19% | Q1 2020 | Q3 2021 | 2 |
| AVALO THERAPEUTICS INC | 2 | 2 | 0.84% | 1.01% | 1.18% | Q3 2021 | Q4 2021 | 2 | |
| DCTH | DELCATH SYSTEMS, INC. | 2 | 2 | 0.76% | 0.84% | 0.92% | Q2 2023 | Q3 2023 | 2 |
| MTNB | MATINAS BIOPHARMA HOLD... | 2 | 2 | 0.40% | 0.83% | 1.26% | Q1 2019 | Q2 2019 | 2 |
| MTEM | MOLECULAR TEMPLATES INC | 2 | 2 | 0.41% | 0.80% | 1.19% | Q3 2018 | Q4 2018 | 2 |
| JNP | Juniper Pharmaceutical... | 2 | 2 | 0.76% | 0.78% | 0.79% | Q3 2016 | Q4 2016 | 2 |
| ALDX | ALDEYRA THERAPEUTICS INC | 1 | 1 | 0.37% | 0.77% | 1.17% | Q3 2018 | Q4 2021 | 2 |
| GEMP | GEMPHIRE THERAPEUTICS INC | 2 | 2 | 0.64% | 0.74% | 0.85% | Q1 2018 | Q2 2018 | 2 |
| XENE | XENON PHARMACEUTICALS INC | 1 | 1 | 0.58% | 0.67% | 0.77% | Q3 2018 | Q1 2019 | 2 |
| VSTM | VERASTEM INC | 1 | 1 | 0.41% | 0.63% | 0.85% | Q4 2017 | Q1 2019 | 2 |
| AERI | AERIE PHARMACEUTICALS INC | 2 | 2 | 0.35% | 0.62% | 0.88% | Q1 2022 | Q2 2022 | 2 |
| APVO | APTEVO THERAPEUTICS INC | 2 | 2 | 0.51% | 0.57% | 0.64% | Q4 2020 | Q1 2021 | 2 |
| CASM | CAS MEDICAL SYSTEMS INC | 2 | 2 | 0.44% | 0.50% | 0.56% | Q2 2017 | Q3 2017 | 2 |
| MARINUS PHARMACEUTICAL... | 2 | 2 | 0.22% | 0.38% | 0.55% | Q1 2022 | Q2 2022 | 2 | |
| AYTU BIOPHARMA INC | 2 | 2 | 0.27% | 0.35% | 0.42% | Q2 2023 | Q3 2023 | 2 | |
| CRVS | CORVUS PHARMACEUTICALS... | 2 | 2 | 0.06% | 0.30% | 0.53% | Q1 2021 | Q2 2021 | 2 |
| NMTC | NEUROONE MEDICAL TECHN... | 2 | 2 | 0.11% | 0.28% | 0.44% | Q4 2021 | Q1 2022 | 2 |
| AQXP | AQUINOX PHARMACEUTICAL... | 2 | 2 | 0.15% | 0.22% | 0.28% | Q4 2017 | Q1 2018 | 2 |
| NBSE | NEUBASE THERAPEUTICS INC | 2 | 2 | 0.08% | 0.13% | 0.18% | Q2 2021 | Q3 2021 | 2 |
| Viveve Medical, Inc | 1 | 1 | 10.93% | 10.93% | 10.93% | Q2 2016 | Q2 2016 | 1 | |
| STML | STEMLINE THERAPEUTICS INC | 1 | 1 | 4.54% | 4.54% | 4.54% | Q1 2020 | Q1 2020 | 1 |
| FMI | FOUNDATION MEDICINE INC | 1 | 1 | 4.27% | 4.27% | 4.27% | Q4 2015 | Q4 2015 | 1 |
| ALIMERA SCIENCES INC | 1 | 1 | 4.10% | 4.10% | 4.10% | Q3 2023 | Q3 2023 | 1 | |
| AEGERION PHARMACEUTICA... | 1 | 1 | 3.47% | 3.47% | 3.47% | Q1 2019 | Q1 2019 | 1 | |
| AEGERION PHARMACEUTICA... | 1 | 1 | 3.05% | 3.05% | 3.05% | Q1 2020 | Q1 2020 | 1 | |
| QDEL | QUIDEL CORP | 1 | 1 | 2.88% | 2.88% | 2.88% | Q1 2022 | Q1 2022 | 1 |
| PERNIX THERAPEUTICS HO... | 1 | 1 | 2.73% | 2.73% | 2.73% | Q1 2016 | Q1 2016 | 1 | |
| PLXP | PLX PHARMA INC | 1 | 1 | 2.47% | 2.47% | 2.47% | Q1 2021 | Q1 2021 | 1 |
| CERC | CERECOR INC | 1 | 1 | 2.27% | 2.27% | 2.27% | Q2 2020 | Q2 2020 | 1 |
| ZLTQ | ZELTIQ Aesthetics, Inc. | 1 | 1 | 2.24% | 2.24% | 2.24% | Q1 2016 | Q1 2016 | 1 |
| AEGERION PHARMACEUTICA... | 1 | 1 | 1.98% | 1.98% | 1.98% | Q4 2019 | Q4 2019 | 1 | |
| NVUS | NOVUS THERAPEUTICS INC | 1 | 1 | 1.97% | 1.97% | 1.97% | Q4 2020 | Q4 2020 | 1 |
| ACAD | ACADIA PHARMACEUTICALS... | 1 | 1 | 1.81% | 1.81% | 1.81% | Q2 2018 | Q2 2018 | 1 |
| CORI | Corium International, ... | 1 | 1 | 1.67% | 1.67% | 1.67% | Q2 2017 | Q2 2017 | 1 |
| BXRX | BAUDAX BIO INC | 1 | 1 | 1.60% | 1.60% | 1.60% | Q1 2020 | Q1 2020 | 1 |
| SPRO | SPERO THERAPEUTICS INC | 1 | 1 | 1.39% | 1.39% | 1.39% | Q3 2018 | Q3 2018 | 1 |
| DVAX | DYNAVAX TECHNOLOGIES CORP | 1 | 1 | 1.37% | 1.37% | 1.37% | Q1 2023 | Q1 2023 | 1 |
| MNKKQ | Mallinckrodt PLC | 1 | 1 | 1.30% | 1.30% | 1.30% | Q4 2016 | Q4 2016 | 1 |
| EIGR | EIGER BIOPHARMACEUTICA... | 1 | 1 | 1.25% | 1.25% | 1.25% | Q4 2017 | Q4 2017 | 1 |
| Enanta Pharmaceuticals... | 1 | 1 | 1.19% | 1.19% | 1.19% | Q2 2016 | Q2 2016 | 1 | |
| IVTY | INVUITY INC | 1 | 1 | 1.05% | 1.05% | 1.05% | Q1 2018 | Q1 2018 | 1 |
| TVTX | TRAVERE THERAPEUTICS INC | 1 | 1 | 1.00% | 1.00% | 1.00% | Q1 2023 | Q1 2023 | 1 |
| SRGA | SURGALIGN HOLDINGS INC | 1 | 1 | 0.93% | 0.93% | 0.93% | Q1 2022 | Q1 2022 | 1 |
| IO BIOTECH INC | 1 | 1 | 0.92% | 0.92% | 0.92% | Q3 2023 | Q3 2023 | 1 | |
| GOSS | GOSSAMER BIO INC | 1 | 1 | 0.92% | 0.92% | 0.92% | Q3 2023 | Q3 2023 | 1 |
| MIRM | MIRUM PHARMACEUTICALS INC | 1 | 1 | 0.89% | 0.89% | 0.89% | Q4 2022 | Q4 2022 | 1 |
| SNDX | SYNDAX PHARMACEUTICALS... | 1 | 1 | 0.85% | 0.85% | 0.85% | Q2 2018 | Q2 2018 | 1 |
| ASRT | ASSERTIO HOLDINGS INC | 1 | 1 | 0.81% | 0.81% | 0.81% | Q3 2023 | Q3 2023 | 1 |
| VTGN | VISTAGEN THERAPEUTICS INC | 1 | 1 | 0.74% | 0.74% | 0.74% | Q4 2020 | Q4 2020 | 1 |
| VICL | VICAL INC | 1 | 1 | 0.74% | 0.74% | 0.74% | Q4 2017 | Q4 2017 | 1 |
| DEPO | Depomed Inc. | 1 | 1 | 0.73% | 0.73% | 0.73% | Q2 2017 | Q2 2017 | 1 |
| CEMI | CHEMBIO DIAGNOSTICS INC | 1 | 1 | 0.73% | 0.73% | 0.73% | Q4 2018 | Q4 2018 | 1 |
| ICPT | INTERCEPT PHARMACEUTIC... | 1 | 1 | 0.64% | 0.64% | 0.64% | Q3 2017 | Q3 2017 | 1 |
| SRRA | SIERRA ONCOLOGY INC | 1 | 1 | 0.63% | 0.63% | 0.63% | Q1 2018 | Q1 2018 | 1 |
| NVTA | INVITAE CORP | 1 | 1 | 0.55% | 0.55% | 0.55% | Q1 2018 | Q1 2018 | 1 |
| ZSAN | ZOSANO PHARMA CORP | 1 | 1 | 0.54% | 0.54% | 0.54% | Q1 2018 | Q1 2018 | 1 |
| OMNIAB INC | 1 | 1 | 0.54% | 0.54% | 0.54% | Q4 2022 | Q4 2022 | 1 | |
| COLL | COLLEGIUM PHARMACEUTIC... | 1 | 1 | 0.52% | 0.52% | 0.52% | Q1 2019 | Q1 2019 | 1 |
| SBPH | SPRING BANK PHARMACEUT... | 1 | 1 | 0.50% | 0.50% | 0.50% | Q3 2018 | Q3 2018 | 1 |
| CBAY | CYMABAY THERAPEUTICS INC | 1 | 1 | 0.46% | 0.46% | 0.46% | Q4 2021 | Q4 2021 | 1 |
| LPTX | LEAP THERAPEUTICS INC | 1 | 1 | 0.46% | 0.46% | 0.46% | Q3 2021 | Q3 2021 | 1 |
| RTRX | RETROPHIN INC | 1 | 1 | 0.33% | 0.33% | 0.33% | Q3 2019 | Q3 2019 | 1 |
| BBI | BRICKELL BIOTECH INC | 1 | 1 | 0.28% | 0.28% | 0.28% | Q2 2020 | Q2 2020 | 1 |
| IMDZ | IMMUNE DESIGN CORP | 1 | 1 | 0.28% | 0.28% | 0.28% | Q1 2018 | Q1 2018 | 1 |
| CBMX | COMBIMATRIX CORP | 1 | 1 | 0.28% | 0.28% | 0.28% | Q3 2017 | Q3 2017 | 1 |
| BWAY | BRAINSWAY LTD | 1 | 1 | 0.27% | 0.27% | 0.27% | Q1 2021 | Q1 2021 | 1 |
| ONCS | ONCOSEC MEDICAL INC | 1 | 1 | 0.24% | 0.24% | 0.24% | Q1 2021 | Q1 2021 | 1 |
| CONFORMIS INC | 1 | 1 | 0.22% | 0.22% | 0.22% | Q1 2023 | Q1 2023 | 1 | |
| EYEN | EYENOVIA INC | 1 | 1 | 0.20% | 0.20% | 0.20% | Q1 2018 | Q1 2018 | 1 |
| SRTS | SENSUS HEALTHCARE INC | 1 | 1 | 0.18% | 0.18% | 0.18% | Q3 2018 | Q3 2018 | 1 |
| CATABASIS PHARMACEUTIC... | 1 | 1 | 0.16% | 0.16% | 0.16% | Q4 2018 | Q4 2018 | 1 | |
| RPTP | Raptor Pharmaceuticals... | 1 | 1 | 0.11% | 0.11% | 0.11% | Q1 2016 | Q1 2016 | 1 |
| IMUX | IMMUNIC INC | 1 | 1 | 0.09% | 0.09% | 0.09% | Q3 2021 | Q3 2021 | 1 |
| TORC | RESTORBIO INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q4 2019 | Q4 2019 | 1 |
| NVIV | INVIVO THERAPEUTICS HO... | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2018 | Q2 2018 | 1 |
| MOTS | MOTUS GI HOLDINGS INC | 1 | 1 | 0.07% | 0.07% | 0.07% | Q2 2019 | Q2 2019 | 1 |
| INSYQ | INSYS Therapeutics, Inc. | 1 | 1 | 0.04% | 0.04% | 0.04% | Q1 2016 | Q1 2016 | 1 |
Download | |||||||||
The securities at the top of the list , including CTI Biopharmap Corp., APOLLO ENDOSURGERY INC, and XOMA CORP, are the highest-conviction holdings of Stonepine Capital Management, LLC.
The conviction is calculated by counting the number of quarters a security has been reported by Stonepine Capital Management, LLC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Stonepine Capital Management, LLC owns currently or has owned in the past.